Beam Therapeutics Past Earnings Performance
Past criteria checks 0/6
Beam Therapeutics's earnings have been declining at an average annual rate of -17.8%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 80.9% per year.
Key information
-17.8%
Earnings growth rate
51.6%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | 80.9% |
| Return on equity | -13.5% |
| Net Margin | -35.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Beam Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 378 | -133 | 117 | 0 |
| 30 Sep 23 | 82 | -285 | 96 | 0 |
| 30 Jun 23 | 80 | -298 | 93 | 0 |
| 31 Mar 23 | 77 | -287 | 92 | 31 |
| 31 Dec 22 | 61 | -289 | 88 | 0 |
| 30 Sep 22 | 92 | -315 | 83 | 0 |
| 30 Jun 22 | 77 | -234 | 77 | 0 |
| 31 Mar 22 | 60 | -238 | 66 | 54 |
| 31 Dec 21 | 52 | -371 | 57 | 0 |
| 30 Sep 21 | 1 | -401 | 48 | -6 |
| 30 Jun 21 | 0 | -408 | 40 | 0 |
| 31 Mar 21 | 0 | -366 | 33 | 0 |
| 31 Dec 20 | 0 | -196 | 30 | 0 |
| 30 Sep 20 | 0 | -132 | 27 | 7 |
| 30 Jun 20 | 0 | -119 | 25 | 2 |
| 31 Mar 20 | 0 | -106 | 23 | 4 |
| 31 Dec 19 | 0 | -91 | 21 | 0 |
| 30 Sep 19 | 0 | -86 | 18 | 8 |
| 30 Jun 19 | 0 | -134 | 15 | 7 |
| 31 Mar 19 | 0 | -124 | 13 | 6 |
| 31 Dec 18 | 0 | -117 | 12 | 6 |
Quality Earnings: BEAM * is currently unprofitable.
Growing Profit Margin: BEAM * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BEAM * is unprofitable, and losses have increased over the past 5 years at a rate of 17.8% per year.
Accelerating Growth: Unable to compare BEAM *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BEAM * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.6%).
Return on Equity
High ROE: BEAM * has a negative Return on Equity (-13.5%), as it is currently unprofitable.